SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 12, 2004
Introgen Therapeutics, Inc.
| Delaware | 0-21291 | 74-2704230 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
||
| 301 Congress Avenue, Suite 1850, Austin, Texas |
78701 | |||
| (Address of principal executive offices) |
(Zip Code) | |||
Registrant’s telephone number, including area code: (512) 708-9310
| Item 7. Financial Statements and Exhibits. | ||||||||
| Item 12. Results of Operations and Financial Condition. | ||||||||
| SIGNATURES | ||||||||
| INDEX TO EXHIBITS | ||||||||
| Press Release | ||||||||
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
99.1 Press Release dated August 12, 2004.
Item 12. Results of Operations and Financial Condition.
On August 12, 2004, Introgen Therapeutics, Inc. issued its press release announcing financial results for the three months ended June 30, 2004. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 12, 2004
|
INTROGEN THERAPEUTICS, INC. | |
| /s/ JAMES W. ALBRECHT, JR. | ||
| James W. Albrecht, Jr. | ||
| Chief Financial Officer |
- 2 -